Kane Biotech Announces Third Quarter 2025 Financial Results

Executive Summary

• Kane Biotech reported Q3 2025 revenue of $8,499 versus $1.28 M in the prior year, reflecting loss of its former animal‑health manufacturing agreement and US distribution partnership.
• The quarter posted a gross loss of $(5.13) M and a net loss of $(0.61) M; operating expenses were cut by roughly 54% to $538k.
• Clinical progress on the revyve® wound‑care platform accelerated, with case‑series enrollment exceeding targets and new pre‑clinical/clinical data presented at multiple U.S. conferences; an FDA 510(k) clearance submission for the revyve Antimicrobial Wound Cleanser was also completed.

Key Details

• Revenue: $8,499 for Q3 2025 (down from $1,282,698 in Q3 2024).
• Gross profit/loss: $(5,128,000) vs. $558,754 in the comparable quarter 2024.
• Operating expenses: $538,306 (down from $1,170,064 YoY), driven by staff reductions and lower compensation & business‑development costs.
• Net loss: $(607,345) for Q3 2025 versus $(678,636) in Q3 2024.
• Cash balance: $939,062 as of September 30, 2025.
• Case‑Series Enrollment: 28 participants enrolled in the revyve Antimicrobial Wound Gel and Spray U.S. case series (target was 25).
• Conference Presentations:
• SAWC Fall conference – clinical data presented; interim CEO met potential distributors.
• DFCon 2025 – diabetic foot ulcer data showing average 97% wound‑area reduction in four weeks and 100% closure within 12 weeks.
• Southern Region Burn Conference – pre‑clinical burn data demonstrating six‑log microbial load reduction in 30 min and ≥7‑day antibiofilm activity.
• Regulatory: Completed FDA 510(k) clearance submission for revyve Antimicrobial Wound Cleanser.
• Commercial Strategy: Ongoing discussions to build a non‑exclusive U.S. distributor and sales‑agent network; plans to launch revyve in Canada.

Notable Quotes

“Kane Biotech is making material progress with our U.S. case series on the revyve wound care gel that has exceeded enrollment targets and is producing compelling clinical data that has been presented at industry conferences,” said Dr. Robert Huizinga, Interim CEO.

Materiality Assessment: Material – Negative (significant decline in revenue and profitability, but includes material operational updates).